VanEck Biotech ETF (NASDAQ:BBH) Sets New 12-Month High – Still a Buy?

Shares of VanEck Biotech ETF (NASDAQ:BBH) reached a new 52-week high during trading on Wednesday. The company traded as high as $254.75 and last traded at $252.9560, with a volume of 14,100 shares. The stock had previously closed at $249.80.

VanEck Biotech ETF Price Performance

The business’s 50-day moving average price is $240.60 and its two-hundred day moving average price is $206.44.

Institutional Trading of VanEck Biotech ETF

Large investors have recently modified their holdings of the business. Nwam LLC bought a new stake in VanEck Biotech ETF during the second quarter valued at $18,614,000. Quantitative Investment Management LLC acquired a new stake in VanEck Biotech ETF during the 2nd quarter worth about $7,589,000. Ascent Advisors LLC acquired a new position in VanEck Biotech ETF in the 1st quarter valued at approximately $11,178,000. Proficio Capital Partners LLC acquired a new position in VanEck Biotech ETF in the second quarter worth approximately $5,183,000. Finally, Bank of America Corp DE increased its holdings in shares of VanEck Biotech ETF by 44.3% during the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock valued at $12,473,000 after acquiring an additional 20,375 shares during the last quarter. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.